Target intelligence / Profile preview

Ankyrin-2 (ANK2)

Target
ANK2
Molecular classification
Cytoskeletal adaptor protein, Membrane-associated scaffolding protein, Ankyrin repeat family, Other (not a receptor, enzyme, or transporter)
01

Overview

Ankyrin-2 (ANK2) is a large, modular cytoskeletal adaptor protein that links transmembrane proteins (such as ion channels and transporters) to the spectrin-actin cytoskeleton. It is ubiquitously expressed, but especially abundant in cardiac muscle and neurons. Ankyrin-2 plays a critical role in the localization and stabilization of key ion regulators including the Na⁺/K⁺ ATPase, Na⁺/Ca²⁺ exchanger, inositol 1,4,5-trisphosphate receptor, and ryanodine receptor at specialized membrane domains in cardiomyocytes and neurons. This ensures coordinated ion handling, electrical excitability, and proper cell signaling. Loss-of-function or pathogenic mutations in ANK2 cause cardiac arrhythmias such as long QT syndrome type 4, sick sinus syndrome, and have been associated with heart failure and abnormal neuro-muscular junctions. Several isoforms exist, reflecting tissue- and context-specific roles. Disruption of ankyrin-2 compromises ion channel targeting and structural integrity of cellular compartments[1][2][3][4][5].

Other names
Ankyrin-BBrain ankyrinNon-erythroid ankyrinANKBFAP87CFAP87LQT4ankyrin 2, neuronalbrank-2
02

Mechanism of action

Not applicable—no known drugs directly target Ankyrin-2. Pathogenic mutations disrupt protein complexes and localization of ion channels and transporters, underlying the mechanism in certain diseases[1][2].

03

Biological functions

Membrane protein anchoringLocalization and stabilization of ion channels and transportersCytoskeleton organizationCell motilityCell activationCell proliferationMaintenance of specialized membrane domainsSignal transduction (especially in neuromuscular junctions and cardiac cells)
04

Disease associations

Cardiovascular disease (including arrhythmias, Long QT syndrome type 4, sick sinus syndrome, heart failure)Neurodevelopmental and neuromuscular disorders (NMJ stability, synaptic maintenance)
05

Safety considerations

Pathogenic variants have pleiotropic cardiac effects including arrhythmias and risk of sudden cardiac death.Disruption may also impact neuronal and muscle function, posing theoretical risks if directly targeted[1][2][3][5].
06

Biomarkers

Long QT syndrome type 4 (LQT4) associated with ANK2 mutation statuspotential biomarker for some cardiac arrhythmias

Beyond the preview

Go deeper on Ankyrin-2 (ANK2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ankyrin-2 (ANK2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call